NYSE:CCChemours Stock Price, Forecast & News

Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CC stock has increased by 54.7% and is now trading at $16.49. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Chemours.

Chemours is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Chemours.

Chemours will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chemours Co (NYSE:CC) issued its quarterly earnings data on Tuesday, May, 5th. The specialty chemicals company reported $0.71 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.46 by $0.25. The specialty chemicals company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.33 billion. Chemours had a negative net margin of 0.82% and a positive return on equity of 56.54%. The company's quarterly revenue was down 5.2% on a year-over-year basis. During the same quarter last year, the business earned $0.63 EPS. View Chemours' earnings history.

Chemours declared a quarterly dividend on Tuesday, April 28th. Investors of record on Friday, May 15th will be given a dividend of $0.25 per share on Monday, June 15th. This represents a $1.00 annualized dividend and a dividend yield of 6.06%. The ex-dividend date of this dividend is Thursday, May 14th. View Chemours' dividend history.

11 brokers have issued 1-year price targets for Chemours' stock. Their forecasts range from $8.00 to $21.00. On average, they anticipate Chemours' stock price to reach $14.00 in the next year. This suggests that the stock has a possible downside of 15.1%. View analysts' price targets for Chemours.

Press coverage about CC stock has trended extremely negative on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chemours earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news stories about the specialty chemicals company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the next several days. View the latest news about Chemours.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), KURARAY CO LTD/ADR (KURRY), W. R. Grace & Co (GRA), Balchem (BCPC), SHOWA DENKO KK/ADR (SHWDY), Univar (UNVR), Ingevity (NGVT), Innospec (IOSP), Olin (OLN), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Hawkins (HWKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA) and Energy Transfer LP Unit (ET).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by a variety of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.53%), Louisiana State Employees Retirement System (0.02%), Envestnet Asset Management Inc. (0.01%), Fruth Investment Management (0.01%) and Patriot Financial Group Insurance Agency LLC (0.00%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View institutional ownership trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, and Envestnet Asset Management Inc.. View insider buying and selling activity for Chemours.

CC stock was purchased by a variety of institutional investors in the last quarter, including Fruth Investment Management, Louisiana State Employees Retirement System, and Patriot Financial Group Insurance Agency LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher. View insider buying and selling activity for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CC stock can currently be purchased for approximately $16.49.

Chemours has a market capitalization of $2.71 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

The official website for Chemours is www.chemours.com.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]